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Seroprevalence of hepatitis A in Maltese adults 
Michael A Borg*, Alfred Portelli** 
ABSTRACT: Objectives: To determine the seroprevalence of hepatitis A virus (HA V) within the 
adult population of Malta. Methods: Serum from blood coincidentally taken for non-acute 
investigations in patients aged 20 - 85 visiting St. Luke's Hospital over a three month period in 1996
- (n = 320) was retrieved and tested for anti-HA V antibodies by Enzyme Immunoassay (Ab bott, 
USA). Results: Seroprevalence levels of anti-HA V antibody in Maltese adults fall into a pattern 
normally associated with low to intermediate prevalence countries. Conclusions: 1. There is a 
statistically significant difference (p<O.OOI) in hepatitis A seroprevalence between the 31-40 and 41­
SO age groups which is not apparent between any other age groups. 2. Seroprevalence rates in the 
under 40's are comparable with studies performed in other European countries in the 
Mediterranean and would therefore indicate that travellers to Malta are at no greater risk of this 
infection than with these destinations. 3. Hepatitis A vaccination is recommended for ' Maltese 
travellers visiting intermediate or highly endemic areas, including countries especially in Eastern 
Europe, the Middle East, Asia, Africa, Central and South America. 4. Serological screening for 
hepatitis A antibodies prior to vaccination appears to be cost-effective in individuals over 40 years 
of age. 
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Introduction 
Viral hepatitis is a relatively common human infection 
which has been known since antiquity'. To-date. the 
viral hepatitis alphabet includes ' five well-defined 
viruses. A to E with two others, F and G being also 
studied as further candidates2J . Hepatitis A (HA V) is a 
highly contagious virus that attacks the liver. It is the 
seventh most commonly reported infectious disease in 
the United States (following gonorrhea. chickenpox. 
syphilis. AIDS . salmonellosis, and shigellosis). 
Worldwide. there are an estimated 1.4 million cases 
annually. 
HA V is a 27 nm icosahedral non-enveloped RNA 
virus with characteristics of the pi corn a group of viruses. 
Originally, it was classified as Enterovirus 72, but 
recently it has been renamed as Heparna virus because of 
differences noted when compared with other 
enteroviruses. The laboratory diagnosis of acute hepatitis 
A infection usually rests on the demonstration of anti­
HA V IgM antibodies in the serum of suspected patients. 
The monitoring of liver enzymes also helps. Anti-HA V 
total antibody tests. many of which do not discriminate 
between the different antibody classes, are usually 
employed to determine immunity against hepatitis A and 
for epidemiological studies. 
The clinical picture of hepatitis A infection varies from 
sub-clinical infections to severe cases with or without 
jaundice. Most cases, especially in young children, are 
sub-clinical. The duration of illness also varies but most 
patients recover in three weeks. The incubation period 
ranges from 20 to 50 days, which means that infectious 
patients. such as food-handlers or children. can spread 
the disease well before they are aware of the infection. 
Most patients recover within three weeks, although some 
have prolonged or relapsing symptoms for up to six 
months4. 
Epidemiology 
Hepatitis A virus is transmitted by the fecal-oral route, 
through close person-to-person contact, or by ingesting 
contaminated food or water. Factors which predispose to 
Hepatitis A transmission include lack of safe drinking 
water, inadequate sewage disposal systems. 
overcrowding, and low socioeconomic and education 
levels. 
In developed countries, people potentially susceptible 
to hepatitis A are predominantly those who travel to less 
developed areas of the world where hepatitis A is 
common. These areas include Africa. Asia (except 
Japan), the Mediterranean basin, Eastern Europe. the 
Middle East, Central and South America, Mexico and 
parts of the Caribbean. Other risk groups include 
individuals who engage in high-risk sexual activity. 
haemophiliacs and other recipients of therapeutic blood 
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products, youngsters in child-care facilities, food­
handlers, healthcare workers who treat patients infected 
with the virus, institutionalized persons and their carers, 
laboratory workers who handle live hepatitis A virus and 
sewage disposal personnel. Historically, the most 
common preventive method has been immune globulin 
administration, which is effective for about three to six 
months. There are now inactivated vaccines that provide 
longer-term protection. These vaccines are typically 
administered as one initial dose followed by a booster in 
about 6 to 18 months. 
World-wide epidemiological studies show a three zone 
model. The introduction of tests for the serological 
markers of hepatitis A infection in the last few years has 
increased the accuracy of epidemiological data. Testing 
for anti-HAV antibodies reveals evidence of past 
infection and world-wide sero-epidemiological studies 
confirm a three zone model for hepatitis A endemicity: 
The first zone comprises high and hyper-endemic 
areas which are normally found in developing countries 
in tropical regions (30 - 100 clinical cases / year per 
100,000 population). Because of the high prevalence of 
the virus and associated poor standards of hygiene, 
exposure occurs predominantly during childhood and 
immunity develops in early Iife5. 
Areas of intermediate endemicity, which make up the 
second zone, are seen in some developing countries 
where standards of hygiene have improved rapidly in 
recent years (20 - 30 clinical cases / year per 100,000 
population). In this zone, the age at which anti-HA V 
antibodies are detected is shifting towards a higher age6. 
In the highly developed countries such as those in 
Northern Europe especially Scandinavia, a third zone of 
low or even hypo-endemicity is recognised with 0 - 15 
clinical cases / year per 100,000 population. These 
countries have a very high standard of hygiene and 
public health. Exposure to hepatitis A virus therefore 
occurs only occasionally. Individuals in this zone are 
susceptible to infection because of low levels of 
circulating HA V and therefore progressive waning of 
immunity year after year? 
Methods 
Subjects (n=320) were recruited from patients aged 
20-85 who visited the hospital over a three month period 
in 1996 according to popUlation, age and sex 
distribution. Expatriates and travellers having spent more 
than three months in a tropical country were excluded 
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from the study. Sera from these individuals were tested 
for the detection of total antibody to Hepatitis A virus by 
an enzyme immunoassay (Havab, Abbott Laboratories). 
Statistical analysis was performed using the Epi-Info 
version 6 software programme. 
Results 
Table 1 depicts the seroprevalence of anti-hepatitis A 
antibodies found in the population studied according to 
age bracket. There is a significant increase (p<O.OO 1) in 
hepatitis A seroprevalence between the 31 - 40 and 41 ­
50 age groups which is not apparent between any other 
age groups. Seroprevalence levels of anti-HAY antibody 
found in Maltese adults fall into a pattern normally 
associated with low to intermediate prevalence countries 
(Fig 1). 
Table 1 - Hepatitis A, seroprevalence according to 
age groups. 
Age cohort n Seroprevalence 
< 30 62 22.4% 
31 - 40 65 41.4% 
41- 50 59 96.3% 
51- 60 64 94.2% 
> 60 70 98.9% 
Discussion 
The Mediterranean littoral is regarded as a high risk 
region for infection with the hepatitis A virus. It is, 
however, the case that during the past decades the 
countries of this region have made major strides forward 
in improving their standard of hygiene through 
considerable civil engineering projects aimed at 
guaranteeing safe water supply and sewage disposal. 
This has been accompanied to a large extent by greater 
awareness of food hygiene. As a result, the prevalence of 
food and water borne illness has decreased markedly and 
infections such as cholera, typhoid and hepatitis have 
dropped to levels at par with those found in more 
northern countries of the region. It would be interesting 
to postulate that the change in hepatitis A seroprevalence 
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evident between individuals in their 30's and those in 
their 40's coincides with major alterations in potable 
water supply which occurred in Malta in the 60's and 
70's. 
The seroprevalence patterns established in this study 
would place Malta as a location of low risk for hepatitis 
A. This conclusion is also corroborated by the reported 
incidence of this infection in this country (Table 2). In 
fact, other than in three years where the yearly figures 
were raised as a result of localized outbreaks, the 
incidence of hepatitis A has consistently been below 1 
case per 100,000 population. 
Our study would seem to indicate that the transmission 
of hepatitis A occurs at a lower level than in other 
European countries of the Mediterranean. In fact, 
Christofidou and colleagues found seroprevalence levels 
of 77.5% in young adults in their 30's in south western 
Greece8 whilst Fernandez-Quintairos and colleagues, 
who performed a similar investigation in north western 
Spain describe seroprevalence levels of more than 80% 
by the age of thirty9 (Table 3). This would indicate that 
travellers to Malta are at no greater risk of hepatitis A 
than in other Mediterranean destinations, or for that 
matter in their country of origin. 
Conclusion 
Hepatitis A remains the most common travel acquired 
infection with an incidence of 1.6 cases per 1000 
travellers per month of travel. Three factors are crucial: 
the country _of origin, the country of travel and the 
duration of stay. Travel from countries of low 
endemicity to others falling in the high or hyper­
endemicity brackets is universally regarded as the most 
significant risk factor. Our data would thus indicate that 
Maltese travellers below 40 years of age visiting high­
risk areas especially in Eastern Europe, the Middle East, 
Asia, Africa, South and Central America are at risk of 
hepatitis A and vaccination is recommended. 
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